I continue to work my way through the ASCO Annual meeting abstracts and news reports. These might be of interest to my readers.
A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7) -- European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial"
The standard chemotherapy for ovarian cancer is carboplatin(C) and paclitaxel(P) every three weeks. This study compared that standard treatment plan with weekly C & P at lower doses. There were 822 women in the study. The study concluded " Compared to standard CP every 3 weeks, weekly CP did not demonstrate a significant benefit in PFS, but was associated with better QoL and toxicity. " (QoL - quality of life PFS Progression free survival)
I had the standard 3 week C&P when I was first diagnosed. If the weekly treatment were to be offered to me today I think I would choose the extra infusion visits for the better quality of life, less fatigue, neutropenia, low platelets etc.
Trabectedin 1.1mg/m2 given as a 3-hour i.v. infusion every 3 weeks was well tolerated and has confirmed a very interesting antitumor activity in this heavily pretreated population and it seems also to be a very tolerable regimen. The co-treatment with dexamethasone improves the safety of Trabectedin by reducing drug-induced myelosuppression and hepatotoxicity. Trabectedin has a manageable toxicity profile, and can be safely administered thanks to its secure action profile also in patients with no other viable therapeutic options.
Survivors of adult onset cancer face a significantly higher amount of psychologic distress, particularly depressive and somatic symptoms, compared to their childhood counterparts and age-expected norms. Analyses are ongoing to evaluate other demographic, disease, and treatment related risk factors that may contribute to this age-related phenomenon in order to develop interventions.